BioSpace News Archive

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced it has received U.S. Food and Drug Administration (FDA) approval on its Abbreviated New Drug Application (ANDA) for Cyclophosphamide for Injection USP, the Company’s AP-rated therapeutic equivalent to Cytoxan® 500 mg, 1 g and 2 g Single-Dose Vials. The Company expects to begin shipping product shortly.

Imprimis Pharmaceuticals, Inc.'s is pleased to announce the findings from a study published in the Journal of Cataract and Refractive Surgery in January 2018.

Accuray Incorporated (NASDAQ: ARAY) announced today that recently published data from two new studies demonstrate the benefits of the TomoTherapy® System in the delivery of total body irradiation (TBI), a procedure commonly used to prepare patients being treated for leukemia and multiple myeloma for a bone marrow transplant. TBI involves irradiation of the entire body, elevating the need for precision, accuracy and homogeneity in radiation dose delivery

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has completed enrollment and dosing of all 5 planned cohorts of healthy adult volunteers in the single-ascending dose portion of its ongoing Phase 1/2 study of ARO-HBV, the company’s third generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a potentially curative therapy for patients with chronic hepatitis B virus (HBV) infection

Technology Enables Clinicians to Non-Invasively Evaluate Brain Blood Flow Characteristics for Management of Patients with Neurological Disease

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced positive results from its interim safety analysis as requested by FDA on patients from its Phase 2 clinical trial of AG013 for the treatment of OM.

Centene Corporation announced it will present at the Goldman Sachs 39th Annual Global Healthcare Conference.

In its report, “An Industry Roadmap for Provider Data,” the Provider Data Action Alliance, a group convened by CAQH, concluded that broad industry collaboration is needed to improve provider data.

Lycera Corp. announced presentations of the company’s novel immuno-oncology therapeutic candidate, LYC-55716, to take place during the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

Eiger BioPharmaceuticals, Inc. announced that David Cory, President and CEO, will present a corporate update at Jefferies 2018 Global Healthcare Conference.